MedPath

Guangzhou Yipinhong Pharmaceutical Co.,Ltd.

Guangzhou Yipinhong Pharmaceutical Co.,Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

8

Active:0
Completed:5

Trial Phases

3 Phases

Phase 1:3
Phase 2:2
Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (42.9%)
Phase 2
2 (28.6%)
Phase 4
2 (28.6%)

The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Chronic Hepatitis B
Interventions
Drug: PNA placebo
First Posted Date
2017-06-08
Last Posted Date
2017-06-08
Lead Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Target Recruit Count
16
Registration Number
NCT03180333
Locations
🇨🇳

Nanjing First Hospital, Nanjing, Jiangsu, China

The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Chronic Hepatitis B
Interventions
Drug: PNA 40mg
Drug: PNA 240mg
Drug: PNA 160mg
Drug: PNA 80mg
Drug: PNA Placebo
Drug: PNA 480mg
Drug: PNA 360mg
First Posted Date
2017-06-02
Last Posted Date
2017-06-02
Lead Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Target Recruit Count
48
Registration Number
NCT03173599
Locations
🇨🇳

Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

First Posted Date
2017-03-15
Last Posted Date
2017-03-15
Lead Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Target Recruit Count
300
Registration Number
NCT03080740
Locations
🇨🇳

Peking University first hospital, Beijing, China

The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Phase 2
Conditions
Chronic Hepatitis B
Interventions
Drug: Metacavir Enteric-coated Capsules 80mg
Drug: Metacavir Enteric-coated Capsules 320mg
Drug: Metacavir Enteric-coated Capsules Placebo 320mg
Drug: Metacavir Enteric-coated Capsules 160mg
Drug: Metacavir Enteric-coated Capsules Placebo 160mg
Drug: Metacavir Enteric-coated Capsules Placebo 240mg
First Posted Date
2016-11-17
Last Posted Date
2016-11-22
Lead Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Target Recruit Count
180
Registration Number
NCT02965859
Locations
🇨🇳

81 Military Hospital of China, Nanjing, Jiangsu, China

The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Cardiovascular Diseases
Interventions
First Posted Date
2016-09-07
Last Posted Date
2016-09-13
Lead Sponsor
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Target Recruit Count
44
Registration Number
NCT02889822
Locations
🇨🇳

The Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.